16:07 EDT Jazz Pharmaceuticals (JAZZ) backs FY25 revenue view $4.15B-$4.4B, consensus $4.29B
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight
- Jazz Pharmaceuticals (JAZZ) Q1 Earnings Cheat Sheet
- Jazz Pharmaceuticals receives CHMP positive opinion for zanidatamab
- Jazz Pharmaceuticals Completes Acquisition of Chimerix
- 3 Value Stocks to Buy amid Trump’s Tariff Turmoil, 4/17/2025, According to Analysts